pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

2,825 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1782Endpoints1388Fierce Biotech706BioSpace698BioPharma Dive524raps234onclive165fda recalls113
therapy area
allOncology12306Rare Disease3217Immunology2862Cardiology2744Hematology2177Pulmonology2138Vaccines
  • Experts discuss emerging role of TROP2-directed ADCs in EGFR-mutated lung cancer
    The segment, part of a series on EGFR‑mutated non‑small cell lung cancer, featured Dr. Jacob Sands together with Drs. Heather Wakelee and Alissa Cooper. They explained that TROP2‑directed antibody…
    onclive · 6mo agoNeutral↗ source
  • Dr. Postow stresses need for long-term multidisciplinary monitoring after melanoma immunotherapy
    Dr. Michael Postow, chief of the Melanoma Service at Memorial Sloan Kettering Cancer Center, emphasizes the importance of long-term multidisciplinary monitoring for patients who have completed immu…
    onclive · 6mo agoNeutral↗ source
← prev
page 103 of 113
next →
fda medwatch111
globenewswire health73
fda press59
1794
Psychiatry & CNS1204
Ophthalmology1060
Pain777
Endocrinology & Metabolism776
Nephrology760
Men less likely to seek suicide help despite higher discussion rates, Crisis Text Line report shows
The nonprofit Crisis Text Line reviewed 1.5 million text messages it received in 2025 and discovered that fewer than one‑fifth of the users identified as male only. Even though men made up a small…
STAT · 6mo agoNegative↗ source
  • Experts discuss treatment sequencing after progression in multiple myeloma
    In a recent video segment, Dr. Ajay K. Nooka, Dr. Noopur S. Raje and Dr. Surbhi Sidana lead a discussion on how to approach treatment sequencing for patients whose multiple myeloma has progressed.…
    onclive · 6mo agoNeutral↗ source
  • Alcohol screening often skipped in primary care, raising health costs
    Doctors are expected to ask patients about their alcohol consumption during routine checkups, but many primary care visits omit or rush this conversation. Evidence-based screening tools can be app…
    STAT · 6mo agoNegative↗ source
  • STAT investigates why alcohol remains America’s leading cause of death and calls for Medicaid work requirement exemptions
    STAT’s D.C. Diagnosis newsletter examines why alcohol continues to be the United States' deadliest drug, highlighting its persistent impact on public health. The piece references cultural commenta…
    STAT · 6mo agoNegative↗ source
  • PCOS renamed PMOS after decade-long scientific effort
    A new name for the condition formerly known as polycystic ovary syndrome (PCOS) has been introduced. The term polyendocrine metabolic ovarian syndrome (PMOS) was presented in a paper published in…
    STAT · 6mo agoPositive↗ source
  • FDA approves brexu-cel CAR-T therapy for relapsed/refractory mantle cell lymphoma, highlighting safety considerations
    The U.S. Food and Drug Administration has granted approval to brexu-cel, a CAR T-cell therapy, for patients with relapsed or refractory mantle cell lymphoma (MCL). This is the first CAR T indicatio…
    onclive · 6mo agoApprovalPositive↗ source
  • Astellas revisits gene therapy for XLMTM, offering new hope after earlier setbacks
    A gene therapy for the rare muscle disorder X‑linked myotubular myopathy (XLMTM) showed mixed results in early trials, with some boys experiencing dramatic recoveries while others died. Astellas P…
    STAT · 6mo agoPositive↗ source
  • Dr. Silbermann highlights trial design priorities for multiple myeloma, from supportive care to diverse enrollment
    Dr. Rebecca Silbermann, an associate professor at Oregon Health & Science University, outlined key considerations for designing multiple myeloma clinical trials. She stressed the importance of alig…
    onclive · 6mo agoNeutral↗ source
  • Supreme Court pauses restrictions, keeps abortion pill mifepristone available through pharmacies and mail
    The Supreme Court issued an order that maintains current access to the abortion medication mifepristone while it reviews a case challenging FDA prescribing rules. The order, signed by Justice Samu…
    STAT · 6mo agoRegulatoryNeutral↗ source
  • Colombian court upholds compulsory license for HIV drug, affirming legal framework
    The Court of Justice of the Andean Community ruled that Colombia's issuance of a compulsory license for an HIV medicine two years ago was lawful. The tribunal said the government had a valid publi…
    STAT · 6mo agoRegulatoryPositive↗ source
  • Zanubrutinib shows longer overall survival than ibrutinib in real-world relapsed/refractory mantle cell lymphoma
    A retrospective real‑world analysis examined outcomes of covalent BTK inhibitors in patients with relapsed or refractory mantle cell lymphoma who received treatment in the second or third line. Th…
    onclive · 6mo agoPositive readoutPositive↗ source
  • Medicare falls short on projected Alzheimer’s drug costs as fewer seniors use Leqembi
    Bob Herman reports that Medicare's earlier estimate that the new Alzheimer's therapy Leqembi would cost the program $3.5 billion in 2025 has proved far too high. The agency's actuaries based the fo…
    STAT · 6mo agoRegulatoryNegative↗ source
  • FDA policy lets some flavored vapes stay on shelves without full approval, raising expert concerns
    The Food and Drug Administration announced a new guidance that allows certain flavored e-cigarettes and nicotine pouches to remain on the market even though they have not received full authorizatio…
    STAT · 6mo agoRegulatoryNegative↗ source
  • INBRX-106 plus pembrolizumab shows higher response rate than pembrolizumab alone in first-line PD-L1-positive head-and-neck cancer
    The HexAgon-HN trial evaluated the OX40 agonist INBRX-106 combined with pembrolizumab in patients with treatment-naive, PD-L1‑positive metastatic or unresectable head‑and‑neck squamous cell carcino…
    onclive · 6mo agoPositive readoutPositive↗ source
  • Astellas therapy brings new hope to rare disease patients amid broader biotech challenges
    A new Astellas treatment is being highlighted as a source of optimism for a community affected by a rare disease, after a period of setbacks in the program. The article also notes a revived gene t…
    STAT · 6mo agoPositive↗ source
  • Medicare uptake of newly approved Alzheimer’s drugs Leqembi and Kisunla falls short of expectations
    Medicare is seeing much lower use of the two Alzheimer’s treatments that received FDA approval earlier this year. The drugs, Leqembi and Kisunla, were expected to generate notable spending for Med…
    STAT · 6mo agoRegulatoryNegative↗ source
  • ctDNA testing shows promise for renal cell carcinoma and germ cell tumors despite current limitations
    Experts discussed how circulating tumor DNA (ctDNA) monitoring, long used in bladder cancer, is being explored for renal cell carcinoma (RCC) and germ cell tumors. In RCC, low tumor shedding has l…
    onclive · 6mo agoNeutral↗ source
  • ctDNA monitoring guides immunotherapy decisions in metastatic urothelial cancer
    Experts discussed how circulating tumor DNA (ctDNA) testing is being used to follow patients with metastatic urothelial carcinoma and to help shape immunotherapy choices. They noted that a rapid d…
    onclive · 6mo agoPositive↗ source
  • Experts call for licensing framework as Utah pauses AI chatbot prescription program
    Alon Bergman, an assistant professor of medical ethics at the University of Pennsylvania, argues that AI-driven medical tools need a licensing system. He points to Utah’s recent pilot with the AI c…
    STAT · 6mo agoRegulatoryNeutral↗ source
  • Medicare cuts projected spending on new Alzheimer’s drugs as uptake remains low
    Medicare is spending far less on the recently approved Alzheimer’s treatments Leqembi and Kisunla than officials had anticipated. The Centers for Medicare and Medicaid Services said the agency does…
    STAT · 6mo agoRegulatoryNegative↗ source
  • Experts highlight growing role of treatment intensification for metastatic castration-sensitive prostate cancer
    During an OncLive Peer Exchange, prostate-cancer specialists examined how treatment intensification is reshaping management of metastatic castration-sensitive prostate cancer. They noted that andr…
    onclive · 6mo agoNeutral↗ source
  • Experts discuss when to start therapy for pediatric low‑grade glioma, weighing chemo, MEK inhibitors and family factors
    In a recent discussion, pediatric neuro‑oncologists examined how to decide when to begin treatment for low‑grade glioma in children. They highlighted the need to balance chemotherapy and MEK inhibi…
    onclive · 6mo agoNeutral↗ source
  • Dr Randall explains rationale for CSF-1R inhibitor pimicotinib in tenosynovial giant cell tumor trial
    Dr Randall, a professor at UC Davis Comprehensive Cancer Center, discussed the clinical reasoning behind testing the selective CSF-1R inhibitor pimicotinib (ABSK021) for tenosynovial giant cell tum…
    onclive · 6mo agoNeutral↗ source